Jingshi B. Wang

YongAn Road 95th Xicheng District, 100050
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Golidocitinib as salvage therapy before allogeneic hematopoietic stem cell transplantation in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Golidocitinib as salvage therapy before allogeneic hematopoietic stem cell transplantation in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Journal: Haematologica

Published: March 31, 2026

Synergistic remediation of Cd-contaminated soil with biochar-sulfate reducing bacteria: Differential roles of straw- and sludge-derived biochars.

Synergistic remediation of Cd-contaminated soil with biochar-sulfate reducing bacteria: Differential roles of straw- and sludge-derived biochars.

Journal: Journal of hazardous materials

Published: August 31, 2025

Hemophagocytic lymphohistiocytosis poses a substantial socio-economic burden in China.

Hemophagocytic lymphohistiocytosis poses a substantial socio-economic burden in China.

Journal: Chinese medical journal

Published: August 21, 2025

The effectiveness of etoposide-containing chemotherapy regimens in the initial treatment of Hemophagocytic Syndrome in pregnancy.

The effectiveness of etoposide-containing chemotherapy regimens in the initial treatment of Hemophagocytic Syndrome in pregnancy.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 06, 2025

Splenectomy does not improve survival in chronic active Epstein-Barr virus disease patients.

Splenectomy does not improve survival in chronic active Epstein-Barr virus disease patients.

Journal: Annals of hematology

Published: July 28, 2025

Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.

Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.

Journal: Annals of hematology

Published: May 14, 2025

Epstein-Barr virus infection plays a crucial role in triggering hemophagocytic lymphohistiocytosis in patients with X-linked inhibitor of apoptosis protein deficiency.

Epstein-Barr virus infection plays a crucial role in triggering hemophagocytic lymphohistiocytosis in patients with X-linked inhibitor of apoptosis protein deficiency.

Journal: Hematology (Amsterdam, Netherlands)

Published: May 13, 2025

Long-Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG-HLH-2018): A Multicenter, Single-Arm Clinical Study.

Long-Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG-HLH-2018): A Multicenter, Single-Arm Clinical Study.

Journal: American journal of hematology

Published: April 19, 2025

Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.

Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.

Journal: Leukemia & lymphoma

Published: March 03, 2025

Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China.

Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China.

Journal: Annals of hematology

Published: November 19, 2024

Diagnosis and treatment of familial hemophagocytic lymphohistiocytosis with isolated central nervous system involvement: A case report.

Diagnosis and treatment of familial hemophagocytic lymphohistiocytosis with isolated central nervous system involvement: A case report.

Journal: Annals of hematology

Published: September 30, 2024

CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).

CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).

Journal: Annals of hematology

Published: July 29, 2024

Showing 1-12 of 78

Last Updated: 09/26/2026